Livmoniplimab, CAS 2412004-88-5

Product Description: Livmoniplimab (ABBV-151; ARGX-115) is a potent, humanized monoclonal antibody against the LRRC32 (GARP)/TGFβ1 complex. Livmoniplimab blocks LRRC32-mediated latent TGFβ1 activation and release. Livmoniplimab has potential in cancer research as a single anticancer agent or in combination with an anti-PD-1 mAb to inhibit locally advanced or metastatic solid tumors (NCT03821935)[1][2][3][4].

Applications: Cancer-Kinase/protease

Formula: N/A

References: [1]Roda D, et al. Livmoniplimab with or without budigalimab in patients with advanced solid tumors: Results from the combination therapy in the urothelial carcinoma dose expansion cohort[J]. 2024./[2]Li A, et al. Selective targeting of GARP-LTGFβ axis in the tumor microenvironment augments PD-1 blockade via enhancing CD8+ T cell antitumor immunity. J Immunother Cancer. 2022 Sep;10(9):e005433.

CAS Number: 2412004-88-5

Molecular Weight: N/A

Compound Purity: 99.25

Research Area: Cancer

Solubility: 10 mM in DMSO

Target: TGF-beta/Smad

• Artikelnummer: MEXHY-P99708-1
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99708-1
• Verpackungseinheit: 1 mg
• Mengeneinheit: STK
• Konjugat: Unconjugated